



Professor Andy Pickett, Ph.D., B.Sc.

**Senior Program Leader & Scientific Expert, Neurotoxins,
Galderma Aesthetic and Corrective
Uppsala, Sweden**

**Director and Founder
Toxin Science Limited**

**Adjunct Professor
Department of Chemistry and Biochemistry
Botulinum Research Center
UMASS Dartmouth
MA, USA**

Graduated in Microbiology in 1975

Doctorate achieved in 1978

Andy Pickett has worked for over 30 years in the pharmaceutical industry on a wide range of biological products including botulinum toxin, microbial enzymes, vaccines, natural products and many recombinant proteins, all in the laboratory, development and also in production and quality.

Andy has worked on botulinum toxin for over 26 years at Ipsen Biopharm Limited, part of the French Ipsen Group (and other predecessor companies) and now in the Galderma Aesthetic and Corrective Business Unit. His activities and responsibilities provided scientific and product support and technical expertise on botulinum toxin structure, function, physiology, assay technologies, quality, regulatory and production areas. He has liaised with many regulatory authorities around the world, including the US Food and Drug Administration, European authorities and the Japanese MHW (now PMDA). He was also responsible for external collaborations, technical support and liaisons with commercial areas. He was the botulinum toxin scientific expert within Ipsen then.

For the last several years, Andy has focused on translating the science and technology of botulinum toxin to enable clinicians, dermatologists, plastic surgeons, rehabilitation specialists and medical students to have a clear understanding of the toxin products available, how they work and how they can be used. His speciality is translating the current, state-of-the-art science into practical knowledge and subsequent benefits for the clinical users and he has been recognised internationally for this work.

Andy has delivered over 300 lectures to audiences worldwide in the last few years. He has lectured at many international conferences, specialist meetings, hospitals, universities and colleges and has been invited to present information to many different clinical disciplines in many different countries. He has also specialised in presenting to aesthetic clinicians on both botulinum toxin and dermal fillers. He has over 50 papers, magazine articles and related publications on botulinum toxin.

Recently, Andy has worked extensively on fake and counterfeit toxin products. He has presented data and published on these illegal products to audiences around the world in order to highlight both their poor quality and potential risks to patients.

Andy founded Toxin Science Limited in 2011 to continue his work on translating the science and technology of botulinum toxin into real, practical meaning for clinicians around the world.

In the autumn of 2011, Andy joined Galderma Aesthetic and Corrective (formerly Q-MED) based in Uppsala, Sweden. He was first responsible for the Development group, which was newly-established during 2011 following the acquisition of Q-MED by Galderma. The Development team was responsible for Clinical Development, Project Management, Microbiology and Stability of all the Q-MED products in the Aesthetic and Corrective portfolio of the company. The Development Team was responsible for the delivery of all new products, product revisions and new technology from after the research stage until first registration in any country, including all necessary clinical trials.

Since May 2014, Andy has focused entirely on botulinum toxin research, process development, clinical development and production within Galderma and is responsible as Senior Program Leader for the botulinum toxin programs currently underway. He is also the Scientific Expert, Neurotoxins within the company.

Currently member of number of professional bodies:

Society of General Microbiology
Society of Chemical Industry
Movement Disorders Society

Member of British Pharmacopoeia Panel of Experts BIO: Biological and Biotechnological Products

Joint inventor on number of patents and patent applications relating to botulinum toxins

Publications 2012-2014

1-24

1. Bakheit AM, Liptrot A, Newton R, Pickett AM. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. *International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation.* 2012;35(1):36-39.
2. Monheit GD, Pickett A. Basic science: Abobotulinumtoxin A. In: Carruthers A, Carruthers J, eds. *Botulinum toxin.* 3rd ed: Elsevier, Inc; 2012.
3. Pickett A. Issues in aesthetic uses of botulinum toxins. *PRIME.* March ed: Prime Journals; 2012:88-91.
4. Pickett A. Documented research reveals evolution of BoNT for aesthetics. *The Aesthetic Guide: Medical Insights, Inc;* 2012:3-10.
5. Pickett A. Characteristics, properties and applications of botulinum toxins in therapeutic use today in the NHS. *British Journal of Medicines Procurement.* 2012;4(1):16-23.
6. Pickett A. Animal studies with botulinum toxins may produce misleading results. *Anesthesia and analgesia.* 2012;115(3):736; author reply 736-737.
7. Pickett A. Expert emphasizes importance of clinically proven neurotoxin products. *The Asian Aesthetic Guide.* Vol 2: Medical Insight Inc; 2012:14-15.
8. Pickett A. The botulinum toxin LD50 potency assay - another chapter, another mystery. *Altern Lab Anim.* 2012;40(4):221-223.
9. Pickett A. Inability of speculation to explain dose effect differences between botulinum toxin products. *Arch Facial Plast Surg.* 2012;14(6):467-468.
10. Pickett A. Toxin Science. *Professional Beauty Magazine.* March/April 2012 ed. Australia: Intermedia; 2012:140-141.
11. Pickett A. In search of quality for BoNT products. *PRIME: Prime Journals;* 2012.
12. Pickett A. Advances in non-surgical facial aesthetics. *Faculty Dental Journal.* 2012;3(4):184-190.
13. Pickett A. Immunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristics. *BioDrugs.* 2013;27(1):83-84.
14. Pickett A. Moderne Ansätze für Botulinumtoxin in der ästhetischen Medizin. *Journal für Ästhetische Chirurgie.* 2013;6(3):166-172.
15. Pickett A. Pearls of the past - gems of the future. *Toxins* 2012; 2013.
16. Pickett A. Reviews of botulinum toxin products in aesthetic use must be accurate, clear and avoid speculation. *Clinical pharmacology : advances and applications.* 2013;5:149-152.
17. Pickett A. Historical aspects of botulinum toxin used clinically: Part I: is that the right serotype? *The Botulinum J.* 2013;2(3/4):176.
18. Pickett A. Toxins and the Fake Market, 2013. IMCAS ASIA, 2013; 2013; Singapore.
19. Pickett AM. Counterfeit botulinum neurotoxin drugs. *Toxicon.* 2013;68(0):72-73.
20. Rzany B, Fratila AA, Fischer TC, et al. Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications. *J Drugs Dermatol.* 2013;12(1):80-84.

21. Pickett A. Botulinum toxin as a clinical product - manufacture and pharmacology. In: Foster K, ed. *Botulinum neurotoxin - molecular understanding and its application*. Vol 2 -Clinical Applications of Botulinum Neurotoxins: Springer Science; 2014.
22. Pickett A. Historical aspects of botulinum toxin used clinically: Part II: overcoming resistance. *The Botulinum J*. 2014:In Press.
23. Pickett A. Counterfeit botulinum medical products and risk of bioterrorism. In: Gopalakrishnakone P, ed. *Handbook of Toxinology. Biological Toxins and Bioterrorisms*. Vol in press: Springer; 2014.
24. Pickett A. Comments on "Anti-photoaging potential of botulinum toxin type A in UVB-induced premature senescence of human dermal fibroblasts in vitro through decreasing senescence-related proteins". *Journal of photochemistry and photobiology. B, Biology*. 2014;138:355.